Biogen Idec makes hostile $356 million bid for Facet
22 September 2009
Sita Shah
Please Login to read the full article.
22 September 2009
Sita Shah
sita.shah@informa.com
Biogen Idec has initiated a tender offer to acquire all of the outstanding shares of Facet Biotech for $14.50 per share in cash. The total deal is valued at $356 million.
The two companies are jointly developing Facet's daclizumab for relapsing multiple sclerosis and volociximab (M200) for...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Valeant prepared to "walk away" from Cephalon if shareholders nix bid
- Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour
- Option deal gives Isis more control in Biogen SMA drug pact
- Teva to buy Cephalon for $6.8 billion, topping Valeant's unsolicited bid
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
